Zoekresultaten - Portaal voor medische datamodellen (MDM-portaal)

Zoekresultaten filteren
Datamodellen selecteren

Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

4 Zoekresultaten.

Eligibility Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma NCT01514344

- 22-06-21 - 1 Formulier, 2 Itemgroepen, 12 Data-elementen, 1 Taal

Itemgroepen: Inclusion Criteria, Exclusion Criteria

Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01514344

Eligibility Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma NCT01514344

- 20-06-21 - 1 Formulier, 2 Itemgroepen, 12 Data-elementen, 1 Taal

Itemgroepen: Inclusion Criteria, Exclusion Criteria

Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01514344

Eligibility B-cell Non Hodgkin Lymphoma NCT01516580

- 19-08-19 - 1 Formulier, 2 Itemgroepen, 18 Data-elementen, 1 Taal

Itemgroepen: Inclusion Criteria, Exclusion Criteria

Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01516580

Screening Biopsy GOAL Trial B-cell Lymphoma NCT02499003

- 20-09-21 - 1 Formulier, 3 Itemgroepen, 22 Data-elementen, 1 Taal

Itemgroepen: Admininstrative data, Bone marrow biopsy, Biopsy Tumor

NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.